ZappRx is a technology company.
ZappRx has raised $40.0M across 3 funding rounds.
ZappRx has raised $40.0M in total across 3 funding rounds.
ZappRx has raised $40.0M in total across 3 funding rounds.
ZappRx's investors include 2048 Ventures, Apollo Health Ventures, BDC Venture Capital, Founder Collective, Qiming Venture Partners USA, Clark Landry, Jeff Seibert, LearnLaunch Accelerator.
ZappRx was a digital health technology company that built a cloud-based platform streamlining the prescription and fulfillment process for specialty medications, particularly for complex conditions like rare diseases in pulmonary and respiratory areas.[1][2][3] It served patients, physicians, pharmacists, and biopharma partners such as Bayer, Genentech, and Teva by automating administrative tasks like electronic prior authorizations and REMS documentation, reducing delays in treatment access.[1][2][5] The platform solved the burdensome, paper-heavy processes that slowed specialty drug delivery, enabling faster medicine access while providing real-time data transparency for providers and pharma companies; ZappRx raised $32.6M–$42M before being acquired by Allscripts (now Veradigm) in June 2019.[1][2]
ZappRx was founded in 2012 in Boston, Massachusetts, by Zoe Barry, inspired by a family member's struggle to access critical medication during illness.[3] Barry, as CEO, developed the idea for a software platform to modernize specialty prescriptions after recognizing gaps in the traditional, inefficient system reliant on faxes and manual checks.[2][3][4] Early traction came from high-profile health system customers and academic medical centers, with the company securing over $40M from investors including Google Ventures, GlaxoSmithKline, and Qiming Venture Partners; a pivotal 2015 Harvard Business School case highlighted Barry's business model debates between exclusive pharma partnerships and an open platform monetized via data sales.[1][3][4]
ZappRx rode the digital health wave transforming specialty pharmacy amid rising demand for high-cost, complex drugs like those for rare diseases, where prior authorizations often delayed care by weeks.[2][4] Timing aligned with EHR integration needs and payer pressures, positioning it against competitors like Phil, Capsule, and Blink Health in e-prescribing and medication access.[1] Market forces favoring it included biopharma's push for patient adherence data and providers' frustration with legacy fax-based systems; its 2019 acquisition by Allscripts bolstered Veradigm's e-prescribing for payers and life sciences, influencing ecosystem-wide efficiency in a space disrupted by Amazon's PillPack and health IT consolidation.[2][7]
Post-acquisition, ZappRx's technology augmented Veradigm's platform, likely enhancing specialty prescribing within Allscripts' EHR ecosystem amid ongoing digital health innovation.[2][7] Trends like AI-driven authorizations and value-based care will shape its legacy, potentially expanding to broader therapeutics as data analytics demand grows. Its influence endures in streamlined specialty workflows, proving a prescient model for collaborative health tech that accelerated patient access in a fragmented market.
ZappRx has raised $40.0M across 3 funding rounds. Most recently, it raised $25.0M Series B in April 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2017 | $25.0M Series B | 2048 Ventures, Apollo Health Ventures, BDC Venture Capital, Founder Collective, Qiming Venture Partners USA, Clark Landry, Jeff Seibert | |
| Apr 1, 2015 | $14.0M Series A | Apollo Health Ventures, BDC Venture Capital | |
| Sep 1, 2013 | $1.0M Seed | LearnLaunch Accelerator, Apollo Health Ventures, BDC Venture Capital |